NCT06662773 - Drug-Drug Interaction (DDI) Study for TQB3616 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2024

Primary Completion Date

March 31, 2025

Study Completion Date

July 31, 2025

Conditions

Healthy

Interventions

DRUG

TQB3616 capsule + itraconazole

C2/4/6 inhibitors + CYP3A metabolic enzyme inhibitors

DRUG

TQB3616 capsule + rifampicin

C2/4/6 inhibitors + Non-specific cytochrome P450 enzyme inducer

Trial Locations (1)

Beijing Tongren Hospital Affiliated to Capital Medical University, Beijing